Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial

Pedro Aide, Carlota Dobaño, Jahit Sacarlal, John Aponte, Inácio Mandomando, Caterina Guinovart, Quique Bassat, Montse Renom, Laura Puyol, Eusebio Macete, Esperanza Herreros, Amanda Leach, Marie-Claude Dubois, Marie Ange Demoitie, Marc Lievens, Johan Vekemans, Christian Loucq, Ripley Ballou, Joe Cohen, Pedro Alonso

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Previous studies with the malaria vaccine RTS,S/AS02A in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis B components of the RTS,S/AS02A vaccine over a 45 months surveillance period in a large phase IIb trial which included 2022 children aged 1–4 years at recruitment. The RTS,S/AS02A vaccine induced high anti-circumsporozoite antibody levels with at least 96% of children remaining seropositive during the entire follow-up period. IgG titers decayed over the first 6 months of follow-up to about 25% of the initial level, but still remained 30-fold higher until month 45 compared to controls. Children with higher levels of naturally acquired immunity at baseline, assessed by blood stage indirect fluorescent antibody test, had slightly higher anti-circumsporozoite levels, after adjusting for the effect of age. The RTS,S/AS02A vaccine also induced high levels of anti-hepatitis B surface antigen antibodies (seroprotection >97%). RTS,S/AS02A vaccine is immunogenic and induces long-lasting anti-circumsporozoite antibodies, persisting at least 42 months after immunization. These antibodies may play a role in protection against malaria.
    Original languageEnglish
    Pages (from-to)6059-6067
    Number of pages9
    JournalVaccine
    Volume29
    Issue number35
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Malaria Vaccines
    immune response
    Malaria
    antibodies
    Plasmodium falciparum
    vaccines
    Antibodies
    Anti-Idiotypic Antibodies
    Mozambique
    Hepatitis B Antibodies
    malaria
    Adaptive Immunity
    Hepatitis B Surface Antigens
    Hepatitis B
    Antibody Formation
    Immunization
    Immunoglobulin G
    hepatitis B
    Safety
    RTS,S-AS02A vaccine

    Cite this

    Aide, P., Dobaño, C., Sacarlal, J., Aponte, J., Mandomando, I., Guinovart, C., ... Alonso, P. (2011). Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial. Vaccine, 29(35), 6059-6067. https://doi.org/10.1016/j.vaccine.2011.03.041
    Aide, Pedro ; Dobaño, Carlota ; Sacarlal, Jahit ; Aponte, John ; Mandomando, Inácio ; Guinovart, Caterina ; Bassat, Quique ; Renom, Montse ; Puyol, Laura ; Macete, Eusebio ; Herreros, Esperanza ; Leach, Amanda ; Dubois, Marie-Claude ; Demoitie, Marie Ange ; Lievens, Marc ; Vekemans, Johan ; Loucq, Christian ; Ballou, Ripley ; Cohen, Joe ; Alonso, Pedro. / Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial. In: Vaccine. 2011 ; Vol. 29, No. 35. pp. 6059-6067.
    @article{eefcdf31863548dd97ce76706a18a7e6,
    title = "Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial",
    abstract = "Previous studies with the malaria vaccine RTS,S/AS02A in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis B components of the RTS,S/AS02A vaccine over a 45 months surveillance period in a large phase IIb trial which included 2022 children aged 1–4 years at recruitment. The RTS,S/AS02A vaccine induced high anti-circumsporozoite antibody levels with at least 96{\%} of children remaining seropositive during the entire follow-up period. IgG titers decayed over the first 6 months of follow-up to about 25{\%} of the initial level, but still remained 30-fold higher until month 45 compared to controls. Children with higher levels of naturally acquired immunity at baseline, assessed by blood stage indirect fluorescent antibody test, had slightly higher anti-circumsporozoite levels, after adjusting for the effect of age. The RTS,S/AS02A vaccine also induced high levels of anti-hepatitis B surface antigen antibodies (seroprotection >97{\%}). RTS,S/AS02A vaccine is immunogenic and induces long-lasting anti-circumsporozoite antibodies, persisting at least 42 months after immunization. These antibodies may play a role in protection against malaria.",
    author = "Pedro Aide and Carlota Doba{\~A}±o and Jahit Sacarlal and John Aponte and In{\~A}¡cio Mandomando and Caterina Guinovart and Quique Bassat and Montse Renom and Laura Puyol and Eusebio Macete and Esperanza Herreros and Amanda Leach and Marie-Claude Dubois and Demoitie, {Marie Ange} and Marc Lievens and Johan Vekemans and Christian Loucq and Ripley Ballou and Joe Cohen and Pedro Alonso",
    year = "2011",
    doi = "10.1016/j.vaccine.2011.03.041",
    language = "English",
    volume = "29",
    pages = "6059--6067",
    journal = "Vaccine",
    issn = "0264-410X",
    publisher = "Elsevier",
    number = "35",

    }

    Aide, P, Dobaño, C, Sacarlal, J, Aponte, J, Mandomando, I, Guinovart, C, Bassat, Q, Renom, M, Puyol, L, Macete, E, Herreros, E, Leach, A, Dubois, M-C, Demoitie, MA, Lievens, M, Vekemans, J, Loucq, C, Ballou, R, Cohen, J & Alonso, P 2011, 'Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial', Vaccine, vol. 29, no. 35, pp. 6059-6067. https://doi.org/10.1016/j.vaccine.2011.03.041

    Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial. / Aide, Pedro; Dobaño, Carlota; Sacarlal, Jahit; Aponte, John; Mandomando, Inácio; Guinovart, Caterina; Bassat, Quique; Renom, Montse; Puyol, Laura; Macete, Eusebio; Herreros, Esperanza; Leach, Amanda; Dubois, Marie-Claude; Demoitie, Marie Ange; Lievens, Marc; Vekemans, Johan; Loucq, Christian; Ballou, Ripley; Cohen, Joe; Alonso, Pedro.

    In: Vaccine, Vol. 29, No. 35, 2011, p. 6059-6067.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial

    AU - Aide, Pedro

    AU - Dobaño, Carlota

    AU - Sacarlal, Jahit

    AU - Aponte, John

    AU - Mandomando, Inácio

    AU - Guinovart, Caterina

    AU - Bassat, Quique

    AU - Renom, Montse

    AU - Puyol, Laura

    AU - Macete, Eusebio

    AU - Herreros, Esperanza

    AU - Leach, Amanda

    AU - Dubois, Marie-Claude

    AU - Demoitie, Marie Ange

    AU - Lievens, Marc

    AU - Vekemans, Johan

    AU - Loucq, Christian

    AU - Ballou, Ripley

    AU - Cohen, Joe

    AU - Alonso, Pedro

    PY - 2011

    Y1 - 2011

    N2 - Previous studies with the malaria vaccine RTS,S/AS02A in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis B components of the RTS,S/AS02A vaccine over a 45 months surveillance period in a large phase IIb trial which included 2022 children aged 1–4 years at recruitment. The RTS,S/AS02A vaccine induced high anti-circumsporozoite antibody levels with at least 96% of children remaining seropositive during the entire follow-up period. IgG titers decayed over the first 6 months of follow-up to about 25% of the initial level, but still remained 30-fold higher until month 45 compared to controls. Children with higher levels of naturally acquired immunity at baseline, assessed by blood stage indirect fluorescent antibody test, had slightly higher anti-circumsporozoite levels, after adjusting for the effect of age. The RTS,S/AS02A vaccine also induced high levels of anti-hepatitis B surface antigen antibodies (seroprotection >97%). RTS,S/AS02A vaccine is immunogenic and induces long-lasting anti-circumsporozoite antibodies, persisting at least 42 months after immunization. These antibodies may play a role in protection against malaria.

    AB - Previous studies with the malaria vaccine RTS,S/AS02A in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis B components of the RTS,S/AS02A vaccine over a 45 months surveillance period in a large phase IIb trial which included 2022 children aged 1–4 years at recruitment. The RTS,S/AS02A vaccine induced high anti-circumsporozoite antibody levels with at least 96% of children remaining seropositive during the entire follow-up period. IgG titers decayed over the first 6 months of follow-up to about 25% of the initial level, but still remained 30-fold higher until month 45 compared to controls. Children with higher levels of naturally acquired immunity at baseline, assessed by blood stage indirect fluorescent antibody test, had slightly higher anti-circumsporozoite levels, after adjusting for the effect of age. The RTS,S/AS02A vaccine also induced high levels of anti-hepatitis B surface antigen antibodies (seroprotection >97%). RTS,S/AS02A vaccine is immunogenic and induces long-lasting anti-circumsporozoite antibodies, persisting at least 42 months after immunization. These antibodies may play a role in protection against malaria.

    U2 - 10.1016/j.vaccine.2011.03.041

    DO - 10.1016/j.vaccine.2011.03.041

    M3 - Article

    VL - 29

    SP - 6059

    EP - 6067

    JO - Vaccine

    JF - Vaccine

    SN - 0264-410X

    IS - 35

    ER -